Tixagevimab and cilgavimab


Entry
D12262            Mixture   Drug                                   
Name
Tixagevimab and cilgavimab;
Tixagevimab (genetical recombination) and cilgavimab (genetical recombination);
Evusheld (TN)
Product
  Other
EVUSHELD (AstraZeneca Pharmaceuticals LP)
Component
Tixagevimab [DR:D11993], Cilgavimab [DR:D11994]
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
ATC code: J06BD03
Product: D12262<US>
Efficacy
Antiviral
  Disease
Coronavirus disease 2019 [DS:H02398]
Comment
For the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19)
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD03 Tixagevimab and cilgavimab
      D12262  Tixagevimab and cilgavimab <US>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12262  Tixagevimab and cilgavimab
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12262  Tixagevimab and cilgavimab
Drug classes [BR:br08332]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12262  Tixagevimab and cilgavimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12262  Tixagevimab and cilgavimab <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12262
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12262
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12262